Nivolumab and Ipilimumab in Advanced Gynecologic Clear Cell Carcinomas: MoST-CIRCUIT Trial

Nivolumab plus ipilimumab achieved a 54% objective response rate and a 6-month PFS rate of 58% in advanced gynecologic clear cell carcinoma.

Prof. Dr. Mustafa Özdoğan
Nivolumab and Ipilimumab in Advanced Gynecologic Clear Cell Carcinomas: MoST-CIRCUIT Trial